Soleus Capital Management L.P. Takes $20.56 Million Position in Inhibikase Therapeutics, Inc. (NYSE:IKT)

Soleus Capital Management L.P. acquired a new stake in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,325,000 shares of the company's stock, valued at approximately $20,556,000. Inhibikase Therapeutics comprises about 1.3% of Soleus Capital Management L.P.'s portfolio, making the stock its 23rd largest holding. Soleus Capital Management L.P. owned about 9.12% of Inhibikase Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of IKT. Stifel Financial Corp bought a new position in Inhibikase Therapeutics in the fourth quarter worth about $43,000. Jefferies Financial Group Inc. bought a new position in Inhibikase Therapeutics in the fourth quarter worth about $48,000. Alpine Global Management LLC bought a new position in Inhibikase Therapeutics in the fourth quarter worth about $48,000. Caxton Corp bought a new position in Inhibikase Therapeutics in the fourth quarter worth about $53,000. Finally, Squarepoint Ops LLC bought a new position in Inhibikase Therapeutics in the fourth quarter worth about $92,000. 3.81% of the stock is owned by institutional investors.

Inhibikase Therapeutics Stock Performance

Shares of NYSE:IKT traded down $0.02 during trading on Wednesday, reaching $1.97. 90,400 shares of the stock traded hands, compared to its average volume of 232,655. The stock has a 50-day moving average of $2.09 and a two-hundred day moving average of $2.48. Inhibikase Therapeutics, Inc. has a 52-week low of $1.12 and a 52-week high of $4.20. The stock has a market cap of $146.45 million, a P/E ratio of -0.74 and a beta of 1.01.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "neutral" rating on shares of Inhibikase Therapeutics in a report on Friday, March 28th.

Inhibikase Therapeutics Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.